UBS Group Cuts Elanco Animal Health (NYSE:ELAN) Price Target to $17.00

Elanco Animal Health (NYSE:ELAN - Get Free Report) had its price objective reduced by equities research analysts at UBS Group from $18.00 to $17.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's target price points to a potential upside of 51.99% from the company's current price.

Other analysts have also recently issued research reports about the stock. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday. Leerink Partners began coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price target on the stock. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday. Finally, Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $15.83.

Elanco Animal Health Stock Up 2.4 %

ELAN stock traded up $0.27 during midday trading on Wednesday, hitting $11.19. The company's stock had a trading volume of 6,902,175 shares, compared to its average volume of 4,960,017. The firm has a 50-day simple moving average of $11.71 and a 200-day simple moving average of $13.03. The firm has a market capitalization of $5.53 billion, a P/E ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the business posted $0.08 earnings per share. The company's revenue for the quarter was down 1.4% on a year-over-year basis. As a group, equities analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $29,000. AM Squared Ltd purchased a new stake in Elanco Animal Health in the third quarter valued at approximately $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock worth $49,000 after acquiring an additional 2,044 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in shares of Elanco Animal Health by 89.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock valued at $50,000 after acquiring an additional 1,601 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.